Protagonist Therapeutics Inc (PTGX)

Return on equity (ROE)

Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019
Net income (ttm) US$ in thousands 162,110 -78,955 -140,484 -137,611 -140,188 -127,393 -130,106 -132,678 -122,483 -125,551 -107,530 -81,489 -70,068 -66,150 -64,765 -73,411 -83,164 -77,187 -73,551 -65,877
Total stockholders’ equity US$ in thousands 560,444 336,677 302,149 294,068 216,167 215,608 243,616 267,978 301,778 300,021 329,660 357,447 259,334 279,606 169,590 167,485 62,666 79,964 95,358 84,316
ROE 28.93% -23.45% -46.49% -46.80% -64.85% -59.09% -53.41% -49.51% -40.59% -41.85% -32.62% -22.80% -27.02% -23.66% -38.19% -43.83% -132.71% -96.53% -77.13% -78.13%

March 31, 2024 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $162,110K ÷ $560,444K
= 28.93%

Protagonist Therapeutics Inc's Return on Equity (ROE) has shown significant fluctuations over the past 20 quarters. The most recent ROE of 28.93% as of March 31, 2024, indicates a strong return generated by the company for its shareholders. This is a positive sign as it shows the company's ability to generate profit from the shareholders' equity.

However, the company experienced negative ROE values in several quarters, with the lowest being -132.71% as of March 31, 2020. Negative ROE values can be a cause for concern as it indicates that the company is not effectively utilizing shareholder funds to generate profits.

The negative ROE values observed in the past could be attributed to various factors such as operational inefficiencies, high debt levels, or poor financial performance. It is important for Protagonist Therapeutics Inc to closely monitor its ROE and take necessary measures to improve profitability and efficiency in order to enhance shareholder value in the long run.


Peer comparison

Mar 31, 2024